Novartis Eyes Gene Therapy Growth With Vedere Acquisition
Paying $150m Upfront
The Swiss major is paying up to $280m to buy Vedere Bio, which has developed photoreceptor-protein based optogenetic therapies that are delivered to the retina intravitreally to restore vision.
